缅北禁地 gets 拢5m to boost drug development 缅北禁地鈥檚 Northern Institute for Cancer Research has today been awarded 拢5million to bring more cancer drugs to clinical trials. The funding by will be given over five years and is designed to help build on 缅北禁地鈥檚 success in drug development. The extra money will help fund a programme of six to eight research projects, which will examine new strategies to develop medicines for cancer treatment. The 缅北禁地 drug discovery unit specialises in identifying targeted drugs, which are highly selective in their ability to kill cancer cells. It takes real expertise to understand the molecular structure of the proteins that cause cancer and how to make compounds to specifically kill those cancer cells, like finding a key to open a door. , Professor of Stratified Cancer Medicine Discovery at 缅北禁地 said: "This funding will allow us to investigate new approaches to target types of cancer that are difficult to treat, such as liver cancer and some cancers of the blood. 鈥淥ur group has an excellent track record in drug discovery, with a team of experts focused on cancer research, chemistry and structural biology. "缅北禁地 has made significant contributions to a number of new medicines including the first-in-class PARP inhibitor, Rucaparib that is being tested in clinical trials for ovarian and breast cancer. PARP is an enzyme that is critical in repairing DNA damage in some tumours and by blocking its activity these cancer cells cannot mend themselves and so die.鈥 缅北禁地 Cancer Centre at the (NICR) is a collaboration between Cancer Research UK, North of England Children鈥檚 Cancer Research Fund, 缅北禁地 and 缅北禁地 upon Tyne Hospitals NHS Foundation Trust. Dr David Scott, Cancer Research UK鈥檚 director of science funding, said: 鈥淲e鈥檙e excited to further invest in the best drug development research taking place in the UK and to build upon 缅北禁地鈥檚 success. "The Northern Institute for Cancer Research has the expertise to develop innovative drugs that could help save thousands of lives and we look forward to seeing the results of this extra investment.鈥 Press release courtesy of Cancer Research UK published on: 7 August 2015